Hypertension
Joint statement for assessing and managing high blood pressure in children and adolescents
19 Apr, 2023 | 13:26h | UTCChapter 1: How to correctly measure blood pressure in children and adolescents – Frontiers in Pediatrics
Chapter 2: How to manage high blood pressure in children and adolescents – Frontiers in Pediatrics
Related:
AHA Scientific Statement | Pediatric primary hypertension: An underrecognized condition
AHA Scientific Statement: Ambulatory blood pressure monitoring in children and adolescents.
Cluster RCT | Salt substitute outperforms salt restriction in lowering blood pressure in older patients
18 Apr, 2023 | 13:30h | UTCSalt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial – Nature Medicine (if the link is paywalled, try this one)
Commentary: Exploring effectiveness of salt substitutes in elderly care facilities – Medical Xpress
Related:
Salt substitutes vs. regular salt: a quick look.
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart (link to abstract – $ for full-text)
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Commentary on Twitter
In a cluster-randomized trial in 48 residential elderly care facilities in China, a low-sodium salt substitute instead of regular salt decreased blood pressure and cardiovascular events, while restricting salt consumption did not show beneficial effects https://t.co/Zp0fWH0aA2
— Nature Medicine (@NatureMedicine) April 13, 2023
Podcast | Resistant hypertension
18 Apr, 2023 | 13:16h | UTC#390 Resistant Hypertension – The Curbsiders
RCT | Heterogeneity in blood pressure response to 4 antihypertensive drugs
17 Apr, 2023 | 13:14h | UTCHeterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial – JAMA (free for a limited period)
News Release: Personalized blood pressure treatment more effective – Uppsala University
Twenty‐four-hour ambulatory blood pressure profile in patients with reflex syncope vs. matched controls
12 Apr, 2023 | 13:21h | UTC
Sodium intake linked to both coronary & carotid atherosclerosis in the Swedish population
10 Apr, 2023 | 13:30h | UTC
Commentary on Twitter
Association between salt intake and both carotid and coronary atherosclerosis in a contemporary community-based cohort 👉https://t.co/sHTCEdu4Uw#EHJOpen @ehjopen @SaDeRosa78 #cardiotwitter
— European Society of Cardiology Journals (@ESC_Journals) April 3, 2023
Blood pressure targets in adults with hypertension | A clinical practice guideline from the AAFP
6 Apr, 2023 | 13:30h | UTCCommentary: AAFP Issues New Clinical Practice Guideline on Hypertension – Annals of Family Medicine
ACC/AHA blood pressure categories | Systematic review of adverse pregnancy outcomes in early pregnancy
6 Apr, 2023 | 12:53h | UTC
Commentary on Twitter
https://twitter.com/AJOG_thegray/status/1641772214830727168
M-A | Impact of antihypertensive therapy on maternal & neonatal outcomes in mild-moderate pregnancy hypertension
6 Apr, 2023 | 12:51h | UTC
Cross-sectional study | Association between sodium intake and coronary and carotid atherosclerosis
4 Apr, 2023 | 13:42h | UTCEditorial: Dietary salt intake and atherosclerosis: an area not fully explored – European Heart Journal Open
News Release: High salt diet associated with hardened arteries even in people with normal blood pressure – European Society of Cardiology
AHA Scientific Statement | Pediatric primary hypertension: An underrecognized condition
3 Apr, 2023 | 14:05h | UTCTop Things to Know: Pediatric Primary Hypertension: An Underrecognized Condition – American Heart Association
News Release: Children with high blood pressure often become adults with high blood pressure – American Heart Association
Commentaries:
The Birth of Pediatric Primary Hypertension – American Heart Association
AHA Highlights Pediatric Hypertension in Scientific Statement – HCP Live
Podcast | Pears in primary aldosteronism, mineralocorticoid receptor antagonists, and renovascular hypertension
29 Mar, 2023 | 13:07h | UTC
Dissecting coffee’s impact: high consumption lowers blood pressure, raises LDL-cholesterol
27 Mar, 2023 | 13:25h | UTC
An evidence-based guide to the efficacy and safety of isometric resistance training in hypertension
23 Mar, 2023 | 12:42h | UTC
The global burden of metabolic disease: data from 2000 to 2019
13 Mar, 2023 | 14:39h | UTCThe global burden of metabolic disease: Data from 2000 to 2019 – Cell Metabolism (free for a limited period)
WHO urges countries to implement comprehensive sodium reduction policies to combat cardiovascular disease
10 Mar, 2023 | 14:43h | UTCSummary:
A new report from the World Health Organization (WHO) has shown that the world needs to catch up to achieve its global target of reducing sodium intake by 30% by 2025. The report highlights that only 5% of WHO member states have mandatory and comprehensive sodium reduction policies.
Sodium, found in table salt and other condiments, increases the risk of heart disease, stroke, and premature death when eaten in excess. Implementing highly cost-effective sodium reduction policies could save an estimated seven million lives globally by 2030.
WHO suggests a number of policies, such as reducing the amount of sodium in food products, introducing front-of-pack labeling, launching mass media campaigns, and enforcing public policies related to food service and sales.
The report urges member states to implement sodium intake reduction policies without delay, and calls on food manufacturers to set ambitious targets for sodium reduction in their products.
Article: WHO global report on sodium intake reduction – World Health Organization
News Release: Massive efforts needed to reduce salt intake and protect lives – World Health Organization
Related:
Adding salt to foods and hazard of premature mortality – European Heart Journal
New WHO benchmarks help countries reduce salt intake and save lives – World Health Organization
WHO global sodium benchmarks for different food categories – World Health Organization
Commentary on Twitter
Eating too much salt is one of the top risk factors for heart disease, stroke, and death.
WHO’s first global report on sodium intake reduction shows only 5% of WHO Member States are protected by mandatory and comprehensive sodium reduction policies👉https://t.co/hiocdiXUiy pic.twitter.com/NXSv0oe7fn
— World Health Organization (WHO) (@WHO) March 9, 2023
Cluster RCT | Effectiveness of a non-physician community health-care provider-led intensive BP intervention vs. usual care on CVD
6 Mar, 2023 | 14:20h | UTCSummary:
The study evaluated the effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention on cardiovascular disease compared to usual care. The trial randomly assigned 326 villages to the intervention or usual care, and recruited individuals aged at least 40 years with hypertension. Trained non-physician community health-care providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol and delivered health coaching for patients in the intervention group during the 36-month follow-up.
The study found that the intervention effectively reduced the risk of cardiovascular disease and all-cause death. There was a significant reduction in systolic blood pressure (23.1 mm Hg) and diastolic blood pressure (9.9 mm Hg) in the intervention group compared to the usual care group, with an increased risk of hypotension in the intervention group.
Article: Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial – The Lancet (link to abstract – $ for full-text)
Related:
Cohort Study: Impact of Community Based Screening for Hypertension in Older Adults
Randomized Trial: Community-Based Interventions to Improve Cardiovascular Risk in High-Risk Patients
Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops
Mean systolic blood pressure above the control threshold in people with treated uncontrolled hypertension in 55 countries
2 Mar, 2023 | 12:48h | UTC
RCT | Endovascular ultrasound renal denervation is modestly effective in the treatment of hypertension
1 Mar, 2023 | 14:11h | UTCSummary: The RADIANCE II randomized clinical trial investigated the efficacy and safety of endovascular ultrasound renal denervation in patients with hypertension without the influence of antihypertensive medications. The trial enrolled 224 patients who were withdrawn from such medications and randomly assigned to receive either ultrasound renal denervation or a sham procedure. Results showed that ultrasound renal denervation reduced ambulatory systolic blood pressure by 6.3 mmHg on average at 2 months, compared to the sham procedure, without any reported adverse events. While these findings suggest that ultrasound renal denervation may be modestly effective in the treatment of hypertension, the short-term follow-up period limits the generalizability of these results to daily practice. Additionally, the clinical relevance of a procedure that reduces blood pressure only after withdrawing blood pressure medications should be considered.
Article: Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Is There a Role for Renal Denervation in the Treatment of Hypertension? – JAMA Cardiology (free for a limited period)
Pooled analysis of 3 sham-controlled trials on ultrasound renal denervation for patients with hypertension
1 Mar, 2023 | 14:10h | UTCSummary: The article reports a patient-level pooled analysis of 3 randomized clinical trials that aimed to determine the effectiveness and safety of ultrasound renal denervation (uRDN) in reducing blood pressure (BP) compared to a sham procedure. The analysis included 506 patients with varying severities of hypertension and found that uRDN was modestly effective in reducing daytime ambulatory systolic BP at 2 months compared to the sham procedure, with a mean difference of 5.9 mmHg. One of the limitations of this analysis is that its findings are restricted to a 2-month follow-up. Additional follow-up from the included trials will be required to examine the durability of the effect and safety data.
Editorial: Is There a Role for Renal Denervation in the Treatment of Hypertension? – JAMA Cardiology (free for a limited period)
[Not published yet] M-A | Too little sodium can be harmful to heart failure patients
24 Feb, 2023 | 13:59h | UTCSummary: New research presented at the American College of Cardiology’s annual scientific session suggests that heart failure patients restricting their dietary sodium intake to levels below the standard recommended maximum of 2.3 grams per day do not have additional benefits and may be at increased risk of death. The study analyzed nine randomized controlled trials that assessed different levels of sodium restriction and found that patients following a diet with a sodium intake target below 2.5 grams per day were 80% more likely to die than those following a diet with a target of 2.5 grams per day or more. The researchers recommend establishing a safe level of sodium consumption instead of overly restricting sodium.
News release: Too Little Sodium Can be Harmful to Heart Failure Patients – American College of Cardiology
Consensus Statement | Renal denervation in the management of hypertension in adults
21 Feb, 2023 | 11:45h | UTC
M-A | Blood pressure lowering effects of B-blockers as add-on or combination therapy
16 Feb, 2023 | 15:10h | UTC
Resistant hypertension: a stepwise approach
10 Feb, 2023 | 13:58h | UTCResistant hypertension: A stepwise approach – Cleveland Clinic Journal of Medicine
Phase 2 RCT | Baxdrostat for treatment-resistant hypertension
6 Feb, 2023 | 13:38h | UTCPhase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Aldosterone has long been a pharmacologic target for the treatment of hypertension. However, a new small-molecule drug called baxdrostat inhibits aldosterone synthase in patients with treatment-resistant hypertension. 1/14 pic.twitter.com/F27WE4Wa1d
— NEJM (@NEJM) February 3, 2023